Companies agree $800m deal for off-the-shelf in vivo CAR-T cell therapy
Drug Discovery World
FEBRUARY 22, 2024
Under the terms of the agreement, the companies plan to combine Kelonia’s iGPS with Xyphos’ ACCEL technology to develop in vivo CAR-T cell therapies targeting up to two programmes. Xyphos will be responsible for the development and commercialisation of products created from the collaborative research.
Let's personalize your content